Literature DB >> 30724413

Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.

Chen-Yu Wang1,2, Shau-Huai Fu3, Rong-Sen Yang4, Fei-Yuan Hsiao1,2,5.   

Abstract

PURPOSE: The objective of this study was to investigate the association between the administration of dipeptidyl peptidase-4 (DPP-4) inhibitors (cumulative duration, timing, and individual substance) and the risk of arthralgia by using a nationwide database with two methodological approaches including cohort and nested case-control study designs.
METHODS: Using Taiwan's National Health Insurance Research Database, we identified patients who were newly prescribed with DPP-4 inhibitors, thiazolidinediones (TZDs), or acarbose between 1 March 2009 and 31 December 2012. The exposure of studied drugs was categorized into five exclusive categories: DPP-4 inhibitor, TZD, acarbose, combined use, or non-use, and assessed in a time-varying manner. Time-dependent Cox proportional hazard models were used to estimate the association between DPP-4 inhibitors and the risk of arthralgia. Particularly, we tested the impact of different cumulative duration, timing, and individual substance of DPP-4 inhibitors use on risk of arthralgia. A corresponding nested case-control study using conditional logistic regression was conducted to verify this association.
RESULTS: An increased risk of arthralgia was observed during the first year after initiating DPP-4 inhibitors (adjusted Hazard Ratio = 1.35; 95% confidence interval [CI], 1.04-1.75) but the risk declined with cumulative use. This duration-response relation was not found in TZDs use and acarbose use. In the nested case-control study, there was a slightly increased risk of arthralgia (aOR = 1.08; 95% CI, 1.04-1.12) associated with current DPP-4 inhibitor use.
CONCLUSION: A relatively higher risk of arthralgia was associated with the initial administration of DPP-4 inhibitors, however, the risk declined among long-term users.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  arthralgia; cohort study; dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors); epidemiology; nested case-control study; pharmacoepidemiology

Mesh:

Substances:

Year:  2019        PMID: 30724413     DOI: 10.1002/pds.4733

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  2 in total

1.  Linagliptin-Induced Arthralgia.

Authors:  Stefanie C Nigro; Jennifer D Goldman
Journal:  Clin Diabetes       Date:  2022-01

Review 2.  Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Carolyn F Deacon
Journal:  Nat Rev Endocrinol       Date:  2020-09-14       Impact factor: 43.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.